Clinical Focus ›› 2025, Vol. 40 ›› Issue (8): 764-768.doi: 10.3969/j.issn.1004-583X.2025.08.017
-
Received:2025-07-01Online:2025-08-20Published:2025-09-05
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.08.017
| [1] | Lupo PJ, Spector LG. Cancer progress and priorities: Childhood cancer[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(6): 1081-1094. |
| [2] | Zahnreich S, Schmidberger H. Childhood cancer: Occurrence, treatment and risk of second primary malignancies[J]. Cancers (Basel), 2021, 13(11):2607. |
| [3] |
Keller KM, Koetsier J, Schild L, et al. The potential of PARP as a therapeutic target across pediatric solid malignancies[J]. BMC Cancer, 2023, 23(1): 310.
doi: 10.1186/s12885-022-10319-7 pmid: 37020198 |
| [4] |
Liu LP, Zong SY, Zhang AL, et al. Early detection of molecular residual disease and risk stratification for children with acute myeloid leukemia via circulating tumor DNA[J]. Clin Cancer Res, 2024, 30(6): 1143-1151.
doi: 10.1158/1078-0432.CCR-23-2589 pmid: 38170574 |
| [5] |
Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades[J]. JAMA Oncol, 2020, 6(3): 350-357.
doi: 10.1001/jamaoncol.2019.5582 pmid: 31895405 |
| [6] | Peterson K, Turos-Cabal M, Salvador AD, et al. Mechanistic insights into medulloblastoma relapse[J]. Pharmacol Ther, 2024, 260: 108673. |
| [7] | Othman J, Potter N, Ivey A, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission[J]. Blood, 2024, 143(19): 1931-1936. |
| [8] | Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer[J]. Nat Med, 2025, 31(6): 1958-1968. |
| [9] | Doculara L, Trahair TN, Bayat N, et al. Circulating tumor DNA in pediatric cancer[J]. Front Mol Biosci, 2022, 9: 885597. |
| [10] |
Lei S, Jia S, Takalkar S, et al. Genomic profiling of circulating tumor DNA for childhood cancers[J]. Leukemia, 2025, 39(2): 420-430.
doi: 10.1038/s41375-024-02461-x pmid: 39523434 |
| [11] | Xu L, Kim ME, Polski A, et al. Establishing the clinical utility of ctDNA analysis for diagnosis, prognosis, and treatment monitoring of retinoblastoma: The aqueous humor liquid biopsy[J]. Cancers (Basel), 2021, 13(6):1282. |
| [12] |
Kahana-Edwin S, Cain LE, Karpelowsky J. Roadmap to liquid biopsy biobanking from pediatric cancers-challenges and opportunities[J]. Biopreserv Biobank, 2021, 19(2): 124-129.
doi: 10.1089/bio.2020.0117 pmid: 33493007 |
| [13] | Vellanki PJ, Ghosh S, Pathak A, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors[J]. J Immunother Cancer, 2023, 11(2):e005344. |
| [14] |
Ni X, Li Z, Li X, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: A cross-sectional study[J]. Lancet, 2022, 400(10357): 1020-1032.
doi: 10.1016/S0140-6736(22)01541-0 pmid: 36154677 |
| [15] | Garcia-Murillas I, Cutts RJ, Walsh-Crestani G, et al. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer[J]. Breast Cancer Res Treat, 2025, 209(3): 493-502. |
| [16] |
Fan H, Wang B, Shi L, et al. Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum m-protein using mass spectrometry (EasyM)[J]. Clin Cancer Res, 2024, 30(6): 1131-1142.
doi: 10.1158/1078-0432.CCR-23-2767 pmid: 38170583 |
| [17] |
Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14(9): 985-990.
doi: 10.1038/nm.1789 pmid: 18670422 |
| [18] |
De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma[J]. Nat Commun, 2015, 6: 8839.
doi: 10.1038/ncomms9839 pmid: 26554728 |
| [19] |
Bosse KR, Giudice AM, Lane MV, et al. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma[J]. Cancer Discov, 2022, 12(12): 2800-2819.
doi: 10.1158/2159-8290.CD-22-0287 pmid: 36108156 |
| [20] | Patel J, Aittaleb R, Doherty R, et al. Liquid biopsy in H3K27M diffuse midline glioma[J]. Neuro Oncol, 2024, 26(Supplement_2): S101-s109. |
| [21] |
Combaret V, Hogarty MD, London WB, et al. Influence of neuroblastoma stage on serum-based detection of MYCN amplification[J]. Pediatr Blood Cancer, 2009, 53(3): 329-331.
doi: 10.1002/pbc.22009 pmid: 19301388 |
| [22] | Pagès M, Rotem D, Gydush G, et al. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine[J]. Neuro Oncol, 2022, 24(8): 1352-1363. |
| [23] | Pierce E, Mautner B, Mort J, et al. MRD in aLL: Optimization and innovations[J]. Curr Hematol Malig Rep, 2022, 17(4): 69-81. |
| [24] | Bellassai N, D'Agata R, Marti A, et al. Detection of tumor DNA in human plasma with a functional pll-based surface layer and plasmonic biosensing[J]. ACS Sens, 2021, 6(6): 2307-2319. |
| [25] |
Escudero L, Llort A, Arias A, et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma[J]. Nat Commun, 2020, 11(1): 5376.
doi: 10.1038/s41467-020-19175-0 pmid: 33110059 |
| [26] |
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5): 548-554.
doi: 10.1038/nm.3519 pmid: 24705333 |
| [27] | Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra24. |
| [28] |
Liu APY, Smith KS, Kumar R, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies[J]. Cancer Cell, 2021, 39(11): 1519-1530.e4.
doi: 10.1016/j.ccell.2021.09.012 pmid: 34678152 |
| [29] | Nelson AJ, Park S, Nelson MD Jr, et al. Aqueous humor liquid biopsy to exclude retinoblastoma for a child with an intraocular mass[J]. Case Rep Ophthalmol, 2025, 16(1): 366-371. |
| [30] | Conway AM, Pearce SP, Clipson A, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary[J]. Nat Commun, 2024, 15(1): 3292. |
| [31] |
Wu Y, Tilley RD, Gooding JJ. Challenges and solutions in developing ultrasensitive biosensors[J]. J Am Chem Soc, 2019, 141(3): 1162-1170.
doi: 10.1021/jacs.8b09397 pmid: 30463401 |
| [32] | Kahana-Edwin S, Cain LE, McCowage G, et al. Neuroblastoma molecular risk-stratification of DNA copy number and ALK genotyping via cell-free circulating tumor DNA profiling[J]. Cancers (Basel), 2021, 13(13):3365. |
| [33] | Nirgude S, Naveh NSS, Kavari SL, et al. Cancer predisposition signaling in beckwith-wiedemann syndrome drives wilms tumor development[J]. Br J Cancer, 2024, 130(4): 638-650. |
| [34] | Abbou S, Klega K, Tsuji J, et al. Circulating tumor DNA is prognostic in intermediate-risk rhabdomyosarcoma: A report from the children's oncology group[J]. J Clin Oncol, 2023, 41(13): 2382-2393. |
| [35] |
Adane B, Alexe G, Seong BKA, et al. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma[J]. Cancer Cell, 2021, 39(6): 827-844.e10.
doi: 10.1016/j.ccell.2021.05.007 pmid: 34129824 |
| [36] | Klega K, Imamovic-Tuco A, Ha G, et al. Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors[J]. JCO Precis Oncol, 2018, 2018:PO.17.00285. |
| [37] |
Saarinen-Pihkala UM, Parto K, Riikonen P, et al. RALLE pilot: Response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children[J]. J Pediatr Hematol Oncol, 2012, 34(4): 263-270.
doi: 10.1097/MPH.0b013e3182352da9 pmid: 22246158 |
| [38] | Zhu GQ, Liu WR, Tang Z, et al. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: A prospective study[J]. Mol Oncol, 2022, 16(2): 549-561. |
| [39] | Fu Y, Xu Y, Liu W, et al. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma[J]. EClinicalMedicine, 2024, 73: 102697. |
| [40] |
Berko ER, Witek GM, Matkar S, et al. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma[J]. Nat Commun, 2023, 14(1): 2601.
doi: 10.1038/s41467-023-38195-0 pmid: 37147298 |
| [41] | Leonetti A, Cervati V, Minari R, et al. Liquid biopsy and 18F-FDG PET/CT derived parameters as predictive factors of osimertinib treatment in advanced EGFR-Mutated NSCLC[J]. Clin Lung Cancer, 2024, 25(8): e436-e45.e9. |
| [42] |
Cabús L, Lagarde J, Curado J, et al. Current challenges and best practices for cell-free long RNA biomarker discovery[J]. Biomark Res, 2022, 10(1): 62.
doi: 10.1186/s40364-022-00409-w pmid: 35978416 |
| [43] |
Godsey JH, Silvestro A, Barrett JC, et al. Generic protocols for the analytical validation of next-generation sequencing-based ctdna assays: A joint consensus recommendation of the BloodPAC's analytical variables working group[J]. Clin Chem, 2020, 66(9): 1156-1166.
doi: 10.1093/clinchem/hvaa164 pmid: 32870995 |
| [44] | Mangum R, Reuther J, Sen Baksi K, et al. Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study[J]. Pediatr Hematol Oncol, 2023, 40(8): 719-738. |
| [45] | Kramer A, Schuuring E, Vessies DCL, et al. A micro-costing framework for circulating tumor DNA testing in dutch clinical practice[J]. J Mol Diagn, 2023, 25(1): 36-45. |
| [46] | Keup C, Kimmig R, Kasimir-Bauer S. Combinatorial power of cfDNA, CTCs and EVs in oncology[J]. Diagnostics (Basel), 2022, 12(4):870. |
| [47] | Liu F, Xiong QW, Wang JH, et al. Roles of lncRNAs in childhood cancer: Current landscape and future perspectives[J]. Front Oncol, 2023, 13: 1060107. |
| [48] | Werutsky G, Barrios CH, Cardona AF, et al. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean[J]. Lancet Oncol, 2021, 22(11): e488-e500. |
| [1] | Wang Hongqian, Fang Xuewen. Effects of family-centered advance care planning on ACP readiness and quality of life in patients with advanced cancer [J]. Clinical Focus, 2024, 39(12): 1106-1110. |
| [2] | . [J]. Clinical Focus, 2024, 39(4): 363-369. |
| [3] | Ye Qian, Ling Zhai, Liu Shenxiang, Lu Guotao, Yin Xudong. Meta analysis on effects of glucocorticoid on the immunotherapy of advanced cancer [J]. Clinical Focus, 2022, 37(7): 591-598. |
| [4] | . [J]. Clinical Focus, 2022, 37(3): 279-284. |
| [5] | LIU Bo-ru;WANG Ren-sheng. Spiral CT differential diagnosis of non thyroid-derived tumor in neck of elderly patients [J]. Clinical Focus, 2014, 29(8): 885-887. |
| [6] | ZHAO Jing-hui;ZHANG Lun;GU Feng;MA Yong-jie;FU Li;HAO Xi-shan. Influence of STAT3 expression on cisplatin sensitivity in head and neck squamous cell carcinoma [J]. CLINICAL FOCUS, 2009, 24(15): 1320-0. |
| [7] | . [J]. CLINICAL FOCUS, 2007, 22(22): 1605-1605. |
| [8] | . [J]. CLINICAL FOCUS, 2004, 19(16): 957-957. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||